Planet 13 Holdings (PLNH) Net Income towards Common Stockholders (2021 - 2026)
Planet 13 Holdings (PLNH) posted quarterly Net Income towards Common Stockholders of -$8.1 million for Q1 2026, down 295.46% year-over-year from $4.1 million in Q1 2025, and down 215.53% quarter-over-quarter from $7.0 million in Q4 2025.
Planet 13 Holdings (PLNH) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
Planet 13 Holdings (PLNH) has reported Net Income towards Common Stockholders for 6 consecutive years, with -$8.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 295.46% year-over-year to -$8.1 million; the TTM figure through Mar 2026 stood at -$58.3 million (down 32.69% YoY), while the FY2025 annual figure was -$52.3 million, down 9.42% from the prior year.
- Net Income towards Common Stockholders fell to -$8.1 million in Q1 2026 per PLNH's latest filing, from $7.0 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $7.0 million in Q4 2025 and bottomed at -$46.3 million in Q3 2023.
- Historically, Net Income towards Common Stockholders has averaged -$14.2 million across 5 years, with a median of -$8.1 million in 2024.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders sank 2131.73% — and 2025, when it jumped 126.5%.
- Planet 13 Holdings' Net Income towards Common Stockholders stood at -$42.1 million in 2022, then surged by 66.13% to -$14.3 million in 2023, then slumped by 85.43% to -$26.4 million in 2024, then surged by 126.5% to $7.0 million in 2025, then plunged by 215.53% to -$8.1 million in 2026.
- Business Quant data shows PLNH's Net Income towards Common Stockholders at -$8.1 million in Q1 2026, $7.0 million in Q4 2025, and -$44.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | 710.19 Mn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Planet 13 Holdings | 47.95 Mn | 31.46 Mn | 12.32 Mn | -5.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.59 Mn |
| Mar 31, 2026 | -8.10 Mn |
| Dec 31, 2025 | 7.01 Mn |
| Sep 30, 2025 | -43.96 Mn |
| Jun 30, 2025 | -13.30 Mn |
| Mar 31, 2025 | -2.05 Mn |
| Dec 31, 2024 | -26.44 Mn |
| Sep 30, 2024 | -7.41 Mn |
| Jun 30, 2024 | -8.07 Mn |
| Mar 31, 2024 | -5.87 Mn |
| Dec 31, 2023 | -14.26 Mn |
| Sep 30, 2023 | -46.25 Mn |
| Jun 30, 2023 | -4.62 Mn |
| Mar 31, 2023 | -8.48 Mn |
| Dec 31, 2022 | -42.09 Mn |
| Sep 30, 2022 | -6.32 Mn |
| Jun 30, 2022 | -7.07 Mn |
| Mar 31, 2022 | -4.06 Mn |
| Dec 31, 2021 | -12.46 Mn |
| Sep 30, 2021 | 4.05 Mn |